Literature DB >> 11420390

Menstrual cycle-specific inhibition of endometrial stromal cell proliferation by oncostatin M.

Y Ohata1, T Harada, A Fujii, S Yoshida, T Iwabe, N Terakawa.   

Abstract

We have investigated the possible roles of oncostatin M (OSM), which is a member of the interleukin-6 family of cytokines, in endometrial and endometriotic stromal cell growth. Endometrial and endometriotic stromal cells were collected from the uterus or ovarian chocolate cysts. We observed the expression of mRNA transcripts for OSM, OSM receptor subunit beta, leukaemia inhibitory factor receptor subunit (LIFR), and glycoprotein 130 in endometrial and endometriotic stromal cells. We also examined the effects of OSM (0-50 ng/ml) and LIF (0-10 ng/ml) on endometrial and endometriotic stromal cell proliferation and evaluated the effects of OSM on endometrial stromal cell differentiation. The presence of 10-50 ng/ml OSM significantly suppressed endometrial stromal cell growth in secretory phase tissue but not in proliferative phase tissue. In contrast, stromal cells in endometriotic tissues were resistant to the inhibitory effects of OSM. Addition of LIF did not influence the growth of endometrial stromal cells. We also showed that 10 ng/ml OSM stimulated markers of differentiation causing increased prolactin secretion and cyclooxygenase-2 gene expression in endometrial stromal cells from the secretory phase. These results suggest that OSM may play a pivotal role in regulating the growth and differentiation of endometrial cells. Endometriotic cells may behave differently from normal endometrial cells in terms of the inhibitory response to OSM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11420390     DOI: 10.1093/molehr/7.7.665

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  7 in total

1.  Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma.

Authors:  Tasneem Kausar; Rinu Sharma; Md Raghibul Hasan; Anoop Saraya; Tushar K Chattopadhyay; Siddartha Datta Gupta; Ranju Ralhan
Journal:  Cell Oncol (Dordr)       Date:  2011-03-11       Impact factor: 6.730

2.  Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer.

Authors:  Myoung Sook Kim; Joost Louwagie; Beatriz Carvalho; Jochim S Terhaar Sive Droste; Hannah Lui Park; Young Kwang Chae; Keishi Yamashita; Junwei Liu; Kimberly Laskie Ostrow; Shizhang Ling; Rafael Guerrero-Preston; Semra Demokan; Zubeyde Yalniz; Nejat Dalay; Gerrit A Meijer; Wim Van Criekinge; David Sidransky
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

3.  Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2.

Authors:  Ryan G Holzer; Randall E Ryan; Matt Tommack; Eric Schlekeway; Cheryl L Jorcyk
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  Development of a prognostic signature for esophageal cancer based on nine immune related genes.

Authors:  Zhi Zhang; Cheng Chen; Ying Fang; Sheng Li; Xiaohua Wang; Lei Sun; Guoren Zhou; Jinjun Ye
Journal:  BMC Cancer       Date:  2021-02-04       Impact factor: 4.430

5.  Comprehensive analysis of a new immune-related prognostic signature for esophageal cancer and its correlation with infiltrating immune cells and target genes.

Authors:  Zhang Peng; Xin-Yuan Liu; Zeng Cheng; Wu Kai; Zhao Song
Journal:  Ann Transl Med       Date:  2021-10

6.  Enhanced effect of recombinant adenoviruses co-expression of ING4 and OSM on anti-tumour activity of laryngeal cancer.

Authors:  Fuwei Cheng; Shuangping Zhao; Jiachen Li; Yuyu Niu; Haiping Huang; Jicheng Yang; Shiyin Ma; Jisheng Liu; Peng Sun
Journal:  J Cell Mol Med       Date:  2022-01-24       Impact factor: 5.310

7.  Establish immune-related gene prognostic index for esophageal cancer.

Authors:  Caiyu Guo; Fanye Zeng; Hui Liu; Jianlin Wang; Xue Huang; Judong Luo
Journal:  Front Genet       Date:  2022-08-09       Impact factor: 4.772

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.